These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20358440)

  • 1. Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):615-31. PubMed ID: 20358440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size and power estimation in "thorough" QT/QTc studies with parallel group design.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2010 May; 20(3):578-86. PubMed ID: 20358437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple comparisons of repeatedly measured response: issues of validation testing in thorough QT/QTc clinical trials.
    Tsong Y; Yan LK; Zhong J; Nie L; Zhang J
    J Biopharm Stat; 2010 May; 20(3):654-64. PubMed ID: 20358443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size calculations for crossover thorough QT studies: satisfaction of regulatory threshold and assay sensitivity.
    Anand SP; Murray SC; Koch GG
    J Biopharm Stat; 2010 May; 20(3):587-603. PubMed ID: 20358438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple comparisons of repeated measured response: issues of assessment of prolongation of QT interval in thorough QT trials.
    Tsong Y; Zhong J
    J Biopharm Stat; 2010 May; 20(3):604-14. PubMed ID: 20358439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of several methods for analyzing data from thorough QT studies.
    Tian H; Qiao W; Natarajan J
    J Biopharm Stat; 2010 May; 20(3):632-40. PubMed ID: 20358441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical consideration in testing for assay sensitivity in a "thorough" QT study.
    Sethuraman V; Wu S; Wang J
    J Biopharm Stat; 2010 May; 20(3):641-53. PubMed ID: 20358442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points.
    Meng Z; Kringle R; Chen X; Zhao PL
    J Biopharm Stat; 2010 May; 20(3):563-77. PubMed ID: 20358436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed effects in the exposure-response analysis of clinical QTc trials.
    Glomb P; Ring A
    J Biopharm Stat; 2012; 22(2):387-400. PubMed ID: 22251181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M; Hnatkova K; Batchvarov V; Gang Y; Smetana P; Camm AJ
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studies.
    Hosmane B; Locke C; Chiu YL
    J Biopharm Stat; 2013; 23(4):871-80. PubMed ID: 23786591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT analysis: a complex answer to a 'simple' problem.
    Li L; Desai M; Desta Z; Flockhart D
    Stat Med; 2004 Sep; 23(17):2625-43. PubMed ID: 15316947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical characterization of QT prolongation.
    Schall R; Ring A
    J Biopharm Stat; 2010 May; 20(3):543-62. PubMed ID: 20358435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bayesian measurement error approach to QT interval correction and prolongation.
    Chen J; Zhao X
    J Biopharm Stat; 2010 May; 20(3):523-42. PubMed ID: 20358434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical characteristics of moxifloxacin-induced QTc effect.
    Yan LK; Zhang J; Ng MJ; Dang Q
    J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the average baseline versus the time-matched baseline in parallel group thorough QT/QTc studies.
    Meng Z; Quan H; Fan L; Kringle R; Sun G
    J Biopharm Stat; 2010 May; 20(3):665-82. PubMed ID: 20358444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A nonparametric approach to QT interval correction for heart rate.
    Wang D; Cheung YB; Arezina R; Taubel J; Camm AJ
    J Biopharm Stat; 2010 May; 20(3):508-22. PubMed ID: 20358433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Further discussion on the design and analysis of thorough QTc clinical trials: guest editors' notes.
    Tsong Y; Zhang J
    J Biopharm Stat; 2010 May; 20(3):493-6. PubMed ID: 20358431
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.